Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.39 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.39 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | USP9X | Q93008 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20889391 | 1.00 | SLC9A1 (0.39) | SLC9A1SLC9A5SLC9A2MTNR1BMTNR1A | |
| SCHEMBL4447693 | 0.79 | HTR2A (0.41) | SLC9A1SLC9A5SLC9A2MTNR1BMTNR1A | |
| SCHEMBL24469522 | 0.79 | HTR2A (0.41) | SLC9A1SLC9A5SLC9A2MTNR1BMTNR1A | |
| SCHEMBL29793765 | 0.79 | HTR2A (0.41) | SLC9A1SLC9A5SLC9A2MTNR1BMTNR1A | |
| SCHEMBL25108307 | 0.78 | USP9X (0.43) | SLC9A1SLC9A5SLC9A2MTNR1BMTNR1A | |
| SCHEMBL19682594 | 0.78 | PARP1 (0.50) | USP9X | |
| SCHEMBL20889270 | 0.78 | PARP1 (0.50) | USP9X | |
| Hydrochloric Acid SCHEMBL22836840 | 0.77 | ALDH1A1 (0.41) | SLC9A1SLC9A5SLC9A2MTNR1BMTNR1A | |
| Hydrochloric Acid SCHEMBL22836841 | 0.77 | ALDH1A1 (0.41) | SLC9A1SLC9A5SLC9A2MTNR1BMTNR1A | |
| Hydrochloric Acid SCHEMBL29042936 | 0.77 | ALDH1A1 (0.41) | SLC9A1SLC9A5SLC9A2MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | SLC9A1 1157/4885SLC9A5 1508/4885SLC9A2 1477/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | SLC9A1 1157/4885SLC9A5 1508/4885SLC9A2 1477/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | SLC9A1 1157/4885SLC9A5 1508/4885SLC9A2 1477/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | SLC9A1 1263/4885SLC9A5 1914/4885SLC9A2 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.